Recently,
compound KA-11 was identified as a promising candidate
for a new broad-spectrum anticonvulsant. This compound revealed wide
protective activity across the most important animal models of seizures
such as the maximal electroshock test (MES), the subcutaneous pentylenetetrazole
test (scPTZ), and the six-hertz test (6 Hz, 32 mA).
Importantly, KA-11 was devoid of acute neurological activity, which
was assessed by applying the chimney test (TD50 value higher
than 1500 mg/kg). The preliminary in vivo results confirmed favorable
anticonvulsant and safety properties of KA-11. With the aim of further
biological characterization of KA-11, in the current studies we evaluated
its antiepileptogenic activity in the kindling model of epilepsy induced
by repeated injection of PTZ in mice. Furthermore, we assessed the
antinociceptive activity of KA-11 in several animal pain models. As
a result, KA-11 (at all doses applied: 25, 50, and 100 mg/kg) significantly
delayed the progression of kindling induced by repeated injection
of PTZ in mice. Additionally, KA-11 revealed potent antinociceptive
activity in the formalin-induced tonic pain and, importantly, in the
oxaliplatin-induced neuropathic pain model in mice. Moreover, KA-11
did not induce motor deficits in the rotarod test. Patch-clamp experiments
revealed that one of the mechanisms of action of KA-11 is inhibition
of voltage-gated sodium currents. Compound KA-11 appeared to be safe in relation to hepatotoxic
properties as no phospholipidosis induction was determined in HepG2
cells at 50 μM, and a small, statistically significant decrease
of cell viability was observed only at the highest used dose of 100
μM. Moreover, KA-11 did not affect the function of CYP2D6. The
aforementioned hybrid substance proved to penetrate the biological
membranes in the in vitro permeability assays.
In this paper we continue to discuss the involvement of essential elements in depression and anxiety, and the possible mechanisms that link elements to the neurobiology underlying depression/anxiety. The present paper is focused on copper, selenium, manganese, iodine and vanadium. Different aspects of relationship between elements and depression or anxiety are reviewed, e.g. the association of the amount of an element in a diet or the serum level of an element and depressive or anxiety-like symptoms. Moreover, the relation of selected elements to the pathophysiology of depression or anxiety is discussed in the context of enzymes which require these elements as co-factors and are involved in the underlying pathophysiology of these disorders.
Preclinical and clinical studies have demonstrated that zinc possesses antidepressant properties and that it may augment the therapy with conventional, that is, monoamine-based, antidepressants. In this review we aim to discuss the role of zinc in the pathophysiology and treatment of depression with regard to the monoamine hypothesis of the disease. Particular attention will be paid to the recently described zinc-sensing GPR39 receptor as well as aspects of zinc deficiency. Furthermore, an attempt will be made to give a possible explanation of the mechanisms by which zinc interacts with the monoamine system in the context of depression and neural plasticity.
Recent data suggests that the glutamatergic system is involved in the pathophysiology and treatment of major depressive disorder (MDD) and that the N-methyl-D-aspartate (NMDA) receptor is a potential target for antidepressant drugs. The magnesium ion blocks the ion channel of the NMDA receptor and prevents its excessive activation. Some preclinical and clinical evidence suggests also that magnesium may be useful in the treatment of depression. The present study investigated the effect of magnesium treatment (10, 15 and 20 mg/kg, given as magnesium hydroaspartate) in the chronic mild stress (CMS) model of depression in rats. Moreover, the effect of CMS and magnesium (with an effective dose) on the level of the proteins related to the glutamatergic system (GluN1, GluN2A, GluN2B and PSD-95) in the hippocampus, prefrontal cortex (PFC) and amygdala were examined. A significant reduction in the sucrose intake induced by CMS was increased by magnesium treatment at a dose of 15 mg/kg, beginning from the third week of administration. Magnesium did not affect this behavioural parameter in the control animals. CMS significantly increased the level of the GluN1 subunit in the amygdala (by 174%) and GluN2A in the hippocampus (by 191%), both of which were significantly attenuated by magnesium treatment. Moreover, magnesium treatment in CMS animals increased the level of GluN2B (by 116%) and PSD-95 (by 150%) in the PFC. The present results for the first time demonstrate the antidepressant-like activity of magnesium in the animal model of anhedonia (CMS), thus indicating the possible involvement of the NMDA/glutamatergic receptors in this activity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.